March 21, 2018 3:48 AM ET


Company Overview of Celyad SA

Company Overview

Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The company’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the company’s preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection cathe...

Rue Edouard Belin 2

Mont-Saint-Guibert,  1435


Founded in 2004

84.6 Employees


32 1 039 41 00


32 1 039 41 41

Key Executives for Celyad SA

CEO & Executive Director
Age: 59
Total Annual Compensation: €562.0K
Compensation as of Fiscal Year 2016.

Celyad SA Key Developments

Celyad SA - Special Call

To consider the topic of CYAD-01 (CAR-T NKG2D) cell therapy for the treatment of blood cancers

Celyad Reports Clinical and Operational Developments for the Third Quarter Ended September 30, 2017

Celyad reported clinical and operational developments for the third quarter ended September 30, 2017. In July 2017, Celyad initiated the SHRINK trial, an open-label Phase 1 study evaluating the safety and clinical activity of multiple doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer. The trial includes a dose escalation and an extension stage. The dose escalation design will include three dose levels adjusted to body weight: up to 1x108, 3x108 and 1x109 CYAD-01 cells. At each dose, patients will receive three successive administrations, two weeks apart, at the specified dose. The dose escalation portion of the study will enroll up to 18 patients and the extension phase will enroll 21 additional patients. SHRINK is being conducted in oncology centers in Belgium. In August 2017, Celyad amended its existing agreements with Celdara Medical LLC and Dartmouth College. Under the amended agreements, Celyad will receive an increased share of future revenues generated by these assets, including revenues from its sublicensees. In return, Celyad paid Celdara Medical and Dartmouth College an upfront payment of $12.5 million (€10.6 million) and $12.5 million worth of Celyad shares at a share price of €32.35 corresponding to a 14% premium versus the prior trading day.

Celyad SA Presents at PiperJaffray 29th Annual Healthcare Conference, Nov-28-2017 04:30 PM

Celyad SA Presents at PiperJaffray 29th Annual Healthcare Conference, Nov-28-2017 04:30 PM. Venue: Lotte New York Palace Hotel, Track 5, Hubbard 1, 5th Floor, New York, New York, United States. Speakers: David Edward Gilham, Vice President of Research & Development, Patrick Jeanmart, CFO & Principal Accounting Officer.

Similar Private Companies By Industry

Company Name Region
ADx NeuroSciences NV Europe
Aelin Therapeutics NV Europe
Apitope International NV Europe
Beta-Cell NV Europe
Bienca S.A. Europe

Recent Private Companies Transactions

Private Placement
August 3, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celyad SA, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at